Clough Capital Partners’s Albany Molecular Research Inc AMRI Stock Holding History

Clough Capital Partners’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-161,360	Closed	-$3.03M	–	194
2016 Q4	$3.03M	Sell	161,360 -329,700	-67%	-$5.6M	0.2%	98
2016 Q3	$8.11M	Sell	491,060 -11,000	-2%	-$163K	0.42%	79
2016 Q2	$6.75M	Sell	502,060 -81,871	-14%	-$1.19M	0.36%	89
2016 Q1	$8.93M	Buy	583,931 +86,831	+17%	+$1.36M	0.42%	76
2015 Q4	$9.87M	Sell	497,100 -4,400	-0.9%	-$83.6K	0.46%	75
2015 Q3	$8.74M	Buy	+501,500	New	+$10.2M	0.38%	72

Other funds holding AMRI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PIP

Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return

ACM

American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return

OWP

Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return

Clough Capital Partners's AMRI Position: Q1 2017 in Review

Clough Capital Partners sold out of Albany Molecular Research Inc (AMRI) in Q1 2017, closing a stake of 161,360 shares — an estimated $3.03M sold.

Clough Capital Partners first reported a position in AMRI in Q3 2015 and held it in 6 quarters. The position peaked at $9.87M in Q4 2015. 139 funds tracked by Wall St. Rank hold AMRI as of Q1 2017.

Clough Capital Partners reported no remaining Albany Molecular Research Inc position as of Q1 2017 after selling out during the quarter.
Clough Capital Partners sold 161,360 Albany Molecular Research Inc shares in Q1 2017, an estimated $3.03M.
Clough Capital Partners first reported a position in Albany Molecular Research Inc in Q3 2015 and held it in 6 quarters.
Clough Capital Partners's Albany Molecular Research Inc position peaked at $9.87M in Q4 2015.
139 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q1 2017.

Based on Clough Capital Partners's 13F filing for Q1 2017, filed 15 May 2017.